71 results about "Meloxicam" patented technology

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The present invention relates to the technical field of veterinary medicinal products and specifically to a composition for the treatment of a skin disease in an animal. The main active ingredients of the composition are rapamycin, miconazole, and meloxicam in a mass ratio of (0.01–10):(0.1–20):(0.1–5) and a solvent mixture of water and polyethylene glycol in which the main active ingredients are soluble. The composition has considerable curative effects on fungal infections on the skin surfaces of animals, with low toxicity and minimal irritation.

The invention provides a melogabalin besylate composite pulse drug release preparation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The melogabalin besylate composite pulse drug release preparation provided by the invention comprises a composite tablet and a film coating coated on the surface of the composite tablet, wherein the composite tablet comprises a slow release layer and a pulse-quick release layer which are laminated; the sustained-release layer is formed by drug-containing sustained-release particles; the pulse-quick release layer is formed by drug-containing pulse pellets and drug-containing quick release particles; the drug-containing pulse pellet comprises a drug-containing pellet core, an isolation layer coating the surface of the drug-containing pellet core, a time-lag layer coating the surface of the isolation layer and an enteric layer coating the surface of the time-lag layer. The melogabalin besylate composite pulse drug release preparation provided by the invention can realize stable and effective release of drugs in the daytime and high-concentration release at night, and can avoid the saturated absorption problem and improve the overall bioavailability at the same time.

The present application relates to a kind of meloxicam benzene sulfonic acid tablets and its preparation method and application, the meloxicam benzene sulfonic acid tablets include stabilizer, the stabilizer is selected from one or more of anhydrous citric acid, polyethylene glycol, sorbitol, crosslinked povidone, sodium acetate trihydrate, anhydrous sodium acetate, nicotinic acid, nicotinamide, polyacrylic acid resin, ascorbic acid palmitate.The stability of meloxicam benzene sulfonic acid tablets prepared according to the prescription of the present application is significantly improved, while the preparation process is simple, and has good application prospect.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The application discloses a preparation method of a key intermediate of meloxicam. The application provides a preparation method of a compound IV, which comprises the following steps: step (1), a reaction of a compound III in a solvent under reflux conditions in the presence of a base; and step (2), a reaction of a product obtained in the step (1) in a solvent to obtain the compound IV. The preparation method is simple, low in cost, high in yield and high in purity, and has a good application prospect in industrial production.

The application discloses a method for constructing a Parkinson's disease animal model with improved survival rate and application thereof, and relates to the biomedical field, and comprises the following steps: S1, injecting a gepefron solution into the abdominal cavity of an experimental mouse; S2, performing brain stereotactic injection on the experimental mouse by using a 6-OHDA solution; S3, injecting meloxicam into the abdominal cavity of the experimental mouse, and dynamically adjusting the dosage of meloxicam based on the daily weight change of the experimental mouse; S4, performing postoperative nursing on the experimental mouse, including nutritional support and graded gavage; and S5, performing behavior testing, pathological verification and inflammation evaluation on the experimental mouse, and obtaining a Parkinson's disease animal model through the above steps. The application has the advantages of high postoperative survival rate of the animal and high success rate of modeling.

This invention discloses a method for preparing melogabalin or its salts. The method involves resolution using a specific chiral resolving agent, S-tetrahydrofuran-2-carboxylic acid, followed by alkalization and hydrolysis to obtain melogabalin. Optionally, it may react with an acid to form a salt. The melogabalin or its salts prepared by this method have high optical purity, high resolution yield, require no complex additional post-processing steps, can be industrially produced, and are inexpensive.

The present invention relates to a method for managing pain, such as acute pain, post-operative pain, or post-procedure pain, by administering meloxicam.

The invention discloses an enzymatic synthesis method of a melogabalin intermediate and related alcohol dehydrogenase, racemic 3-ethyl bicyclo [3.2. 0] hept-3-ene-6-ketone is used as a substrate, a genetically engineered bacterium for producing alcohol dehydrogenase is used as an enzyme catalyst, a genetically engineered bacterium for producing formate dehydrogenase, ammonium formate and coenzyme are matched, an enzymatic reaction is carried out under a stirring condition, and the melogabalin intermediate is obtained. And carrying out purification and separation on a reaction product to obtain the melogabalin intermediate (1R, 5S)-3-ethyl bicyclo [3.2. 0] hept-3-ene-6-ketone. The method has the advantages of simple reaction, few steps, mild reaction, less pollution and the like, and has great industrial application potential and commercial value.

This application discloses a method to solubilize poorly soluble drugs in a liquid crystal vehicle for long-acting injectables. Poorly soluble acidic drugs-hydrophobic basic compounds ion pairs are incorporated into liquid crystal vehicles to solubilize and slowly release the drug after parenteral administration. Ion pairs such as Meloxicam-Dodecylamine, Sulfadiazine-Dodecylamine, Methotrexate-Dodecylamine, Levothyroxine-Dodecylamine, Meloxicam-Tridodecylamine, and Meloxicam-Bupivacaine are incorporated into liquid crystal vehicles to solubilize and control release the drugs.

The present application belongs to the field of pharmaceutical preparations, and relates to a meloxicam composition, preparation and preparation method and application. One aspect of the present application provides a meloxicam composition, which comprises meloxicam and a latent solvent, wherein the latent solvent is a mixed solvent comprising water and an organic solvent. Another aspect of the present application provides another composition, which comprises meloxicam, a solvent and a pH regulator, wherein the pH regulator at least comprises citric acid. The pharmaceutical composition of the present application can significantly improve the solubility of meloxicam in liquid preparation, and has excellent stability. The meloxicam composition provided by the present application can even be directly used for intravenous injection administration, and quickly reaches an effective therapeutic concentration for postoperative analgesia. In addition, the preparation process of the composition is simple, and can be completed by stirring and dispersing at room temperature for a short time, so that the scale-up production is easy to realize.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The application discloses a multiple controlled-release drug-loaded coating modified anti-heterotopic ossification artificial temporomandibular joint prosthesis and a preparation method thereof, and comprises the following steps: surface treatment of a biomimetic artificial temporomandibular joint prosthesis; dopamine assisted co-deposition is adopted to sequentially form a DF-HA self-assembled nanosphere coating and a meloxicam liposome drug-loaded coating on the surface of the biomimetic artificial temporomandibular joint porous titanium prosthesis; and RGD is grafted on the surface of the meloxicam liposome drug-loaded coating by chemical natural deposition, and the anti-heterotopic ossification artificial temporomandibular joint prosthesis is obtained. The artificial temporomandibular joint prosthesis is modified by active drug-loaded meloxicam liposomes on one hand, and the artificial temporomandibular joint prosthesis is modified by RGD-DF-HA layered drug loading on the other hand, long-term slow release and programmed release of drugs are realized, anti-inflammatory effects are achieved, the purpose of treating and preventing heterotopic ossification after artificial joint replacement is achieved, long-term stability of artificial joint replacement is beneficial, early prevention, intervention, service life of the artificial joint prosthesis is improved, and the life quality of patients is improved.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a meloxicam nano-micelle preparation for injection and a preparation method of the meloxicam nano-micelle preparation. The meloxicam nano-micelle preparation disclosed by the invention mainly comprises meloxicam and a polyether / polyester block copolymer. The micelle composition disclosed by the invention does not contain auxiliary material components such as a solubilizer and a conventional surfactant, and has better safety, and the micelle disintegrates rapidly to release the medicine from the polymer in a free form, so that the micelle composition has a faster and long-acting analgesic effect.

The invention discloses a melogabalin besylate-containing pharmaceutical composition and a preparation method thereof, the preparation prescription adopts vitamin E polyethylene glycol succinate, gallic acid or tocopheryl succinate as antioxidants, and the specific antioxidants are screened out, so that the prepared melogabalin besylate pharmaceutical composition is better in stability and better in curative effect. Oxidative degradation impurities are effectively controlled, and the effectiveness and safety of melogabalin besylate are improved. In addition, the preparation method is stable, controllable and easy to amplify.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention relates to the technical field of preparation of natural antibacterial neutral agents, and discloses a preparation method of a natural antibacterial neutral agent based on a PLGA slow release mechanism, which comprises the following steps: taking polylactic acid PLGA as a carrier, mixing meloxicam polylactic acid microspheres, a chitosan solution and a cross-linking agent solution, adding a surfactant, and stirring to form a uniform emulsion; adding the emulsion into a hardening agent, and stirring until the cross-linking reaction is completed to obtain chitosan microspheres; the chitosan microspheres are washed with deionized water, and the surfactant and the cross-linking agent remaining on the surfaces are removed; and drying the chitosan microspheres in a ventilation drying chamber to obtain the natural antibacterial neutral agent based on the PLGA slow release mechanism. The meloxicam polylactic acid microspheres are prepared by taking PLGA as a carrier, so that the slow release effect of the medicine can be realized. The sustained release of the drug on the skin surface is facilitated, so that the balance of the pH value of the skin is maintained for a longer time, and the repair of the skin barrier and the maintenance of the microbial balance are promoted.

The application discloses a kind of meloxicam benzenesulfonic acid oral disintegration tablets and preparation method thereof, belong to pharmaceutical preparation technical field, the oral disintegration tablet includes granule / powder A, granule / powder B and auxiliary material;Wherein, the granule / powder A includes: meloxicam benzenesulfonic acid, mannitol, antioxidant, stabilizer, first binder and first disintegrating agent;The antioxidant is butylated hydroxyanisole, and the stabilizer is tartaric acid and / or magnesium metasilicate aluminum;The granule / powder B includes: filler, mannitol, second binder and second disintegrating agent;The auxiliary material includes third disintegrating agent, potassium acetylsulfanate and magnesium stearate.The application is by adjusting tartaric acid, butylated hydroxyanisole, magnesium metasilicate aluminum and the matching of filler, adjusts granulation mixing mode and changes tabletting tablet type, so that the related substance of meloxicam benzenesulfonic acid oral disintegration tablet increases significantly slower, disintegration is significantly faster, solve the technical problem existing in prior art.

The invention belongs to the technical field of crystal form drug molecules, and particularly relates to ketorolac salt of melogabalin and a preparation method of the ketorolac salt. The ketorolac salt of melogabalin provided by the invention is radiated by Cu-K alpha, and an X-ray diffraction spectrum expressed by 2 theta has characteristic peaks at least at the positions of 3.95 + / -0.2 degrees, 4.34 + / -0.2 degrees, 5.19 + / -0.2 degrees, 10.42 + / -0.2 degrees and 14.48 + / -0.2 degrees. The crystal form is good in stability, has remarkably improved dissolving property and pharmacokinetic effect, and is high in patent medicine value; the preparation method is simple to operate, the crystallization process is easy to control, and the reproducibility is good.

The invention discloses a melogabalin besylate raw material capable of controlling particle size distribution, a preparation of the melogabalin besylate raw material, and a preparation process and application of the preparation, and belongs to the technical field of pharmaceutical preparations. The technical problem to be solved is to improve the stability, mixing uniformity and dissolution rate of the melogabalin besylate preparation. According to the technical scheme, the melogabalin besylate raw material capable of controlling particle size distribution is characterized in that the particle size ranges of the melogabalin besylate raw material are as follows: D90 is 130-210 [mu] m, and D50 is 44-71 [mu] m. According to the melogabalin besylate preparation, through the synergistic effect of the specific stabilizer, the characteristics of uniformity and quick release of the product are ensured, the generation of degraded impurities is effectively controlled, and the product quality is stable and controllable.

The present application belongs to the field of veterinary chemical medicine preparation, and specifically discloses a compound alpha-fentanyl injection. The injection takes alpha-fentanyl and meloxicam as main active ingredients, and preferably adds a suspending agent and a surfactant. Specifically, the injection contains 1-10% of alpha-fentanyl, 0.03-0.3% of meloxicam, 0.5-5% of the suspending agent, 0.5-5% of the surfactant, and the rest is water for injection. The injection is a water-based nanoscale injection, has small irritancy, good stability, simple preparation process, low production cost, and is suitable for industrial mass production.

The utility model relates to a medicine powder subpackaging metering device technical field, especially for a kind of meloxicam sodium medicine powder subpackaging's metering equipment for injection, including subpackaging box, the top of subpackaging box is equipped with feed hopper, the bottom of subpackaging box is fixedly connected with conical discharge hopper, the bottom of subpackaging box is fixedly connected with support plate, the bottom of support plate is fixedly connected with mobile base, the top of mobile base is provided with meter, the top of feed hopper is provided with plugging mechanism, plugging mechanism includes firm plate, the outside of firm plate is slidably connected with link block, the inside of firm plate is equipped with lifting groove, the outside of link block is fixedly connected with slide rod, the outside of slide rod is fixedly connected with plugging plate, in the utility model, through the sealing plate and feed hopper caliber adaptation, the sealing property when plugging can be guaranteed, reduce the waste caused by leakage in the medicine powder feeding process, avoid the impurity of outside to enter simultaneously, guarantee the purity of medicine powder, meet the strict sanitary requirement of injection medicine.

The invention belongs to the technical field of separation and purification of melogabalin, and discloses a resolution method of melogabalin, which comprises the following steps: adding racemic melogabalin into dichloromethane, heating and dissolving to obtain a clear solution; cooling the obtained clear solution, adding a melogabalin seed crystal into the clear solution to form (1R, 5S, 6S), and stirring to crystallize; after crystal growing, filtering and drying to obtain a target product. According to the method, a target configuration product can be directly obtained without a resolution reagent, and the process steps are shortened. The chiral purity of the obtained target product is 98% or above.

We provide a combination containing meloxicam and rizatriptan. [Solution] A composition is disclosed comprising an NSAID such as meloxicam and / or rizatriptan in combination with cyclodextrin and / or carbonate or bicarbonate. These compositions can be administered orally to improve the bioavailability or pharmacokinetics of NSAIDs for the treatment of pain such as migraines, arthritis, and other conditions. Also provided is a method for treating pain such as migraines, comprising administering meloxicam and rizatriptan to a person suffering from pain such as migraines. These methods may be particularly useful when administering meloxicam and rizatriptan while a person is suffering from an acute migraine attack or aura. In some embodiments, the combination of meloxicam and rizatriptan is used, with meloxicam being T max It may be administered so that the time interval is 3 hours or less.

The present invention provides a solid composition comprising the following components: (a) bromhexine or a salt thereof; (b) a nonionic surfactant; and (c) a compound selected from the group consisting of vitamin antioxidants, phenolic antioxidants, meloxicam, and acetaminophen (wherein R1 represents a hydrogen atom or a hydrogen atom). The pharmaceutical composition does not contain ibuprofen, clemastine fumarate, dihydrocodeine phosphate, noscapine, racemic methyephedrine hydrochloride, anhydrous caffeine, bromhexine hydrochloride, tranexamic acid, riboflavin, benfotiamine, ascorbic acid, hesperidin, D-mannitol, low-substitution-degree hydroxy propyl cellulose, crystalline cellulose, hydroxy propyl cellulose and polyoxyethylene hydrogenated castor oil 60, and the pharmaceutical composition can be used for preparing the pharmaceutical composition. The invention relates to a solid composition of hydroxypropyl methylcellulose, talc, hydroxy propyl cellulose and light anhydrous silicic acid.

This invention relates to a 30 mg bilayer biphasic-release tablet containing merogabarine or a pharmaceutically acceptable salt thereof, and a method for preparing the same. The tablet is a bilayer tablet consisting of an immediate-release layer and a sustained-release layer, wherein the immediate-release layer accounts for 20%–35% of the total drug content, and the sustained-release layer accounts for 65%–80% of the total drug content. The sustained-release layer contains hydroxypropyl methylcellulose K15M or hydroxypropyl methylcellulose K100M and ethylcellulose. Under the conditions of the second method for release determination in the current edition of the Chinese Pharmacopoeia, the tablet has a predetermined 24-hour release window in any of the media selected from pH 1.2, pH 4.5, and pH 6.8, and maintains a small difference in media values ​​at 8 hours and 12 hours, making it suitable for development into an oral sustained-release formulation for once-daily administration.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.